West Pharmaceutical Services opened higher at $419.06, compared with its previous close of $416.67. In the last trading session, the stock traded between $407.67 and $422.08. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in West Pharmaceutical Services is now worth
$ 95.60
resulting in a loss of
$ 4.40 (4.40%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-5.70 (-1.37%)
Day High
$422.08
Day Low
$407.67
Day Open
$419.06
Prev Close
$416.67
Volume
3,54,476
1W Return
4.29%
1M Return
9.10%
3M Return
21.78%
6M Return
39.14%
1Y Return
44.27%
Fundamentals
Market Cap ($ Mn)
28,923
PE Ratio
43.21
PB Ratio
7.95
PEG Ratio
16.26
ROE
17.00%
ROCE
17.57%
EPS (TTM)
$2.19
Investment Returns
1 Week
4.29%
1 Month
9.10%
3 Months
21.78%
6 Months
39.14%
9 Months
76.65%
Financials
Quarterly
All values in $ Mn
698.0
Mar 25
766.5
Jun 25
804.6
Sep 25
805.0
Dec 25
844.9
Mar 26
872.3
Jun 26
Updates
20Oct
West Pharma raises quarterly dividend 18% to $0.26 per share
West Pharmaceutical Services declared a Q4 dividend of $0.26 per share. The payout represents an 18% increase from the previous quarter's $0.22. This marks the company's 34th consecutive annual dividend increase. Payment is scheduled for November 18, 2026, to shareholders of record on November 11, 2026.
10 days ago
23Jul
West Pharmaceutical raises FY2026 sales and EPS guidance
West Pharmaceutical Services increased its FY2026 adjusted EPS guidance to $8.85-$9.05 and sales outlook to $3.345 billion-$3.380 billion, surpassing analyst estimates of $8.61 and $3.332 billion, respectively. For the third quarter, the company projects sales of $820.000 million-$835.000 million and adjusted EPS of $2.14-$2.24, both above consensus.
3mo ago
22Jul
West Pharmaceutical Services declares $0.22 quarterly dividend
West Pharmaceutical Services declared a regular quarterly dividend of $0.22 per share, payable on August 5, 2026, to shareholders of record on July 29, 2026. The company reported $3.07 billion in net sales for fiscal year 2025.
3mo ago
15Jul
West Pharmaceutical amends distribution and cross-licensing pacts
West Pharmaceutical Services and Daikyo Seiko have amended their distribution and cross-licensing agreements for a 10-year term. The deals involve sharing technology for medical components and grant West exclusive distribution rights outside Japan.
3mo ago
14Jul
BNP Paribas initiates coverage on West Pharmaceutical with Outperform rating
BNP Paribas analyst Curtis Moiles initiates coverage on West Pharmaceutical Services with an Outperform rating and a price target of $447.
3mo ago
10Jul
Morgan Stanley raises West Pharmaceutical target to $365
Morgan Stanley analyst Kallum Titchmarsh maintained an Equal-Weight rating on West Pharmaceutical Services (NYSE: WST) and raised the price target to $365 from $325, indicating a revised valuation outlook.
